April 10, 2007 - Bayer HealthCare Pharmaceuticals Inc. announced its official U.S. launch. The new company incorporates the former Berlex Inc. into Bayer HealthCare Pharmaceuticals, as part of Bayer's acquisition of Schering AG, Germany, Berlex's former parent company.

Bayer HealthCare Pharmaceuticals Inc., headquartered in Wayne, NJ, is the U.S.-based pharmaceuticals unit of Bayer HealthCare. Bayer HealthCare's pharmaceutical business is dedicated to developing, manufacturing and marketing products that help improve human health, and globally ranks among the top 10 specialty pharmaceutical companies. The global pharmaceutical business employs more than 40,000 people, with approximately 5,500 employees in the U.S.

The company's global Oncology and Specialized Therapeutics business units, as well as certain U.S.-based global drug development groups and other business support functions, will be housed in its Montville, N.J. offices. The establishment of Bayer HealthCare Pharmaceuticals is expected to bring an estimated 300 new jobs to New Jersey.

The combined company has a robust research and development program with a strong product pipeline geared toward developing meaningful new therapeutic options to fulfill unmet medical needs. As a result of these two companies combining forces, research and development activities have been consolidated into three major sites (Berkeley, Calif., Berlin and Wuppertal, Germany). The Berkeley facility is an important R&D center for protein-based biologics and will house the company's global Hematology/Cardiology business.

Research in Diagnostic Imaging, Women's Healthcare and Oncology will be based in Berlin. Wuppertal will house the core of the company's Cardiology research. Both locations have significant capabilities and activities in target discovery, lead generation and optimization, drug metabolism and pharmacokinetics, toxicology and clinical pharmacology.

Bayer also will continue operations in Washington State to manufacture the company's white blood cell growth factor.

For more information, contact www.berlex.com.


Related Content

News | Image Guided Radiation Therapy (IGRT)

June 7, 2022 — Two-year results from the Dysphagia-Aspiration Related Structures (DARS) trial, which is funded by Cancer ...

Time June 07, 2022
arrow
News | Image Guided Radiation Therapy (IGRT)

May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...

Time May 19, 2022
arrow
News | Radiation Oncology

August 27, 2021 — For decades, the National Comprehensive Cancer Network (NCCN) recommended forgoing post-lumpectomy ...

Time August 27, 2021
arrow
News | Radiation Therapy

June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...

Time June 10, 2020
arrow
News | Radiation Therapy

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time April 16, 2020
arrow
News | Image Guided Radiation Therapy (IGRT)

February 11, 2020 — Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive ...

Time February 11, 2020
arrow
News | Radiology Imaging

December 12, 2019 — Philips and the Regional Medical Center (RMC) announced a strategic 5-year partnership agreement ...

Time December 12, 2019
arrow
News | Radiation Therapy

October 22, 2019 — The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) ...

Time October 22, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).

Time October 08, 2019
arrow
News | Image Guided Radiation Therapy (IGRT)

At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian announced Ethos therapy, an artificial intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.

Time September 16, 2019
arrow
Subscribe Now